Sort   by:  
 Page size 
UnknownPartial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.
Not available
S-EPMC10178837 | biostudies-literature
UnknownToll-Like Receptor 9 Agonists in Cancer.
Not available
S-EPMC7553670 | biostudies-literature
UnknownACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19.
Not available
S-EPMC7372174 | biostudies-literature
UnknownDebating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era.
Not available
S-EPMC10852382 | biostudies-literature
UnknownClinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.
Not available
S-EPMC12605714 | biostudies-literature
UnknownLead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma.
Not available
S-EPMC12637783 | biostudies-literature
UnknownBMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
Not available
S-EPMC6878694 | biostudies-literature
UnknownExpression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes.
Not available
S-EPMC10332263 | biostudies-literature
UnknownTumor cell p38 inhibition to overcome immunotherapy resistance.
Not available
S-EPMC10462255 | biostudies-literature
UnknownPhase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors.
Not available
S-EPMC12911810 | biostudies-literature
Sort   by:  
 Page size